ArticleAnnals of translational medicine2021
Real-world data on the clinicopathological traits and outcomes of hospitalized liver hemangioma patients: a multicenter study.
Article in Annals of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Hepatic hemangioma: proportion and predictor of surgical treatment with emphasis on its growth rate.The Korean journal of internal medicine · 2023Trial
- Laparoscopic anatomical liver resection versus enucleation in the treatment of giant hepatic hemangioma larger than 10 cm: a retrospective study.BMC surgery · 2026Article
- Clinical outcomes of combined transarterial chemoembolization and microwave ablation for hepatic hemangiomas: a comparative analysis of large versus. giant tumors.BMC gastroenterology · 2025Article
- Efficacy and safety of transcatheter arterial chemoembolization combined with microwave ablation for hepatic hemangiomas (> 5 cm).World journal of gastroenterology · 2025Article
- A report of 12 cases of congenital hepatic hemangioma and literature review.Frontiers in pediatrics · 2025Article
- Retrospective analysis based on a clinical grading system for patients with hepatic hemangioma: A single center experience.World journal of gastrointestinal surgery · 2024Article
- Surgical management of a 25-cm giant hepatic haemangioma: First case report from Bangladesh with literature review.International journal of surgery case reports · 2024Article
- Immunologic landscape of human hepatic hemangiomas and epithelioid hemangioendotheliomas.Hepatology communications · 2024Article
- Transarterial embolization for rare spontaneous subacute intratumoral hemorrhage of hepatic hemangioma: a case report and literature review.Translational cancer research · 2022Article
- The surgical outcomes and risk factors of giant hepatic haemangiomas: a single centre experience.BMC surgery · 2022Article
- Risk factors for hypercoagulability after laparoscopic hepatic haemangioma resection.Journal of minimal access surgeryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is currently a lack of consensus regarding the clinical features, diagnosis, treatment indications and options, and risk assessment of hepatic hemangioma patients.
methodsThis was a multicenter, real-world study that analyzed a large number of hepatic hemangioma cases in China and included patient data on epidemiology, diagnosis, treatment methods, and outcomes.
resultsA total of 5,143 patients hospitalized for hepatic hemangioma were included, of whom 34.42% were male and 65.58% were female. The age distribution was concentrated between 30 and 60 years old, accounting for 87.41% of the patients. Among the hepatic hemangioma patients, 60.8% had only one tumor, with the most common pathological type being cavernous hemangioma (96.07% of cases). The treatment motivations and indications included anxiety, obvious clinical symptoms, rapid tumor growth, unclear diagnoses and acute emergencies. Overall, 41.4% of the patients were treated for psychological reasons, while 30.59% were treated because they presented obvious (primarily nonspecific) clinical symptoms. Hepatic resection was the main therapeutic method and was based on various indications. There were a small number of patients with Kasabach-Merritt syndrome, according to its generally recognized definition.
conclusionsMost patients in this study who were hospitalized for hepatic hemangioma did not meet the indications for requiring treatment. Surveillance is the recommended course of action for definitively diagnosed hepatic hemangioma, and a new classification system is needed to standardize the diagnosis of this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.